|Nom||Titre||Payer||Exercé||Année de naissance|
|Mr. Adam H. Schechter||Pres, CEO & Chairman||5,51M||S.O.||1965|
|Mr. Glenn A. Eisenberg||CFO & Exec. VP||2,3M||S.O.||1961|
|Dr. Brian J. Caveney M.P.H., M.D., J.D., MPH||Exec. VP, Pres of Diagnostics & Chief Medical Officer||1,57M||S.O.||1974|
|Mr. Mark S. Schroeder||Exec. VP and Pres of Diagnostics Laboratory Operations & Global Supply Chain||1,59M||S.O.||1961|
|Dr. Paul R. Kirchgraber M.D.||Exec. VP & CEO of Covance Drug Devel.||2,02M||S.O.||1962|
|Dr. Michelle Abelson Ph.D.||Laboratory Director of Operations||S.O.||S.O.||S.O.|
|Mr. Peter J. Wilkinson||Sr. VP & Chief Accounting Officer||S.O.||S.O.||1972|
|Mr. Lance V. Berberian||Exec. VP and Chief Information & Technology Officer||S.O.||S.O.||1963|
|Dr. Marcia T. Eisenberg Ph.D.||Chief Scientific Officer & Sr. VP||S.O.||S.O.||1960|
|Chas Cook||VP of Investor Relations||S.O.||S.O.||S.O.|
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations. It offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. Laboratory Corporation of America Holdings has a collaboration agreement with Tigerlily Foundation to increase clinical trial diversity for women of color. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
L’ISS Governance QualityScore de Laboratory Corporation of America Holdings en date du 1 juillet 2022 est 1. Les scores principaux sont Audit : 8; Société : 7; Droits des actionnaires : 1; Compensation : 1.